187
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Identification of a Vulnerable Group for Post-Acute Sequelae of SARS-CoV-2 (PASC): People with Autoimmune Diseases Recover More Slowly from COVID-19

ORCID Icon, , , , , & show all
Pages 3941-3949 | Published online: 26 Jul 2021

References

  • Yelin D, Margalit I, Yahav D, Runold M, Bruchfeld J. Long COVID-19-it’s not over until? Clin Microbiol Infect. 2020;S1198-743X(20)30750-3.
  • Baang JH, Smith C, Mirabelli C, et al. Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient. J Infect Dis. 2021;223(1):23–27. doi:10.1093/infdis/jiaa666
  • Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol. 2021;33(2):155–162. doi:10.1097/BOR.0000000000000776
  • Dreyer NA, Reynolds M, Mack CD, et al. Self-reported symptoms from exposure to COVID-19 provide support to clinical diagnosis, triage and prognosis: an exploratory analysis. Travel Med Infect Dis. 2020;38:101909. doi:10.1016/j.tmaid.2020.101909
  • U.S. Department of Health and Human Services, Food and Drug Administration. Assessing COVID-19-related symptoms in outpatient adults and adolescent subjects in clinical trials of drugs and biological products for COVID-19 treatment and prevention. Guidance for industry; September 2020. Available from: https://www.fda.gov/media/142143/download. Accessed March 23, 2021.
  • Huang C, Huang L, Wang Y, et al. Six-month consequences of COVID-19 in patients discharged from hospital: a Cohort Study. Lancet. 2021;397(10270):220–232. doi:10.1016/S0140-6736(20)32656-8
  • El Sayed S, Shokry D, Gomaa SM. Post-COVID-19 fatigue and anhedonia: a Cross-Sectional Study and their correlation to post-recovery period. Neuropsychopharmacol Rep. 2021;41(1):50–55. doi:10.1002/npr2.12154
  • Venkatesan P. NICE guideline on long COVID. Lancet Respir Med. 2021;9(2):129. doi:10.1016/S2213-2600(21)00031-X
  • van der Sar-van der Brugge S, Talman S, Boonman-de Winter L, et al. Pulmonary function and health-related quality of life after COVID-19 pneumonia. Respir Med. 2021;176:106272. doi:10.1016/j.rmed.2020.106272
  • Cortés-Telles A, López-Romero S, Figueroa-Hurtado E, et al. Pulmonary function and functional capacity in COVID-19 survivors with persistent dyspnea. Respir Physiol Neurobiol. 2021;288:103644. doi:10.1016/j.resp.2021.103644
  • Rashedi J, Mahdavi Poor B, Asgharzadeh V, et al. Risk factors for COVID-19. Infez Med. 2020;28(4):469–474.
  • Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626–631. doi:10.1038/s41591-021-01292-y
  • Dreyer NA, Blackburn SCF, Mt-Isa S, et al. Direct-to-patient research: piloting a new approach to understanding drug safety during pregnancy. JMIR Public Health Surveill. 2015;1(2):e22. doi:10.2196/publichealth.4939
  • Fung M, Babik JM. COVID-19 in immunocompromised hosts: what we know so far. Clin Infect Dis. 2020;72:ciaa863.
  • Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a Multicenter Study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783–791. doi:10.1158/2159-8290.CD-20-0422
  • Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a Cohort Study [published correction appears in Lancet. 2020 Sep 12;396(10253):758]. Lancet. 2020;395(10241):1907–1918. doi:10.1016/S0140-6736(20)31187-9
  • Montero F, Martínez-Barrio J, Serrano-Benavente B, et al. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes. Rheumatol Int. 2020;40(10):1593–1598. doi:10.1007/s00296-020-04676-4
  • Scoppettuolo P, Borrelli S, Naeije G. Neurological involvement in SARS-CoV-2 infection: a clinical systematic review. Brain Behav Immun Health. 2020;5:100094. doi:10.1016/j.bbih.2020.100094
  • Blumentals WA, Arreglado A, Napalkov P, Toovey S. Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a Retrospective Cohort Study. BMC Musculoskelet Disord. 2012;27(13):158. doi:10.1186/1471-2474-13-158
  • Alhazzani W, Evans L, Alshamsi F, et al. Surviving sepsis campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update. Crit Care Med. 2021;49(3):e219–e234. doi:10.1097/CCM.0000000000004899
  • Snow TAC, Saleem N, Ambler G, Nastouli E, Singer M, Arulkumaran N. Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials. Intensive Care Med. 2021;21:1–12.